Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Biopharma was not exempt from the initial shock of a global pandemic, but the worst projections have not happened and the initial beneficiaries have now emerged.
After a near universal first quarter stumble, big and medium cap pharma companies finished the half in style, with stocks up $190bn since the end of 2019. The picture is even better for young drug developers, as the Nasdaq biotech index hit an all-time high, up 17% from January. Medtechs have found the first half of 2020 more challenging, with success or failure largely defined by their product’s ability to help in the fight against COVID-19.
Discover what has driven the remarkable turn-around for biopharma and why biotech is on track for a record year for venture finance, despite the global pandemic.